N-butyl pyridinium tetrafluoroborate

We are N-butyl pyridinium tetrafluoroborate CAS:203389-28-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


English Name: N-butyl pyridinium tetrafluoroborate
Synonyms:1-Butylpyridinium Tetrafluoroborate
1-butylpyridin-1-ium tetrafluoroborate
N-butylpyridinium tetrafluoroborate
Molecular Formula: C9H14BF4N
Molecular Weight: 223.12
CAS No.: 203389-28-0
Purity: 99%
 
Technical Information

Appearance:	Purity:
NMR: Passed	null
Solubility:	Insolubility:
Impurity content: (1) Halogen content: < 1000 ppm; (2) Water content: < 1000 ppm

 
Physics-Chemistry Properties

Melting point: -50 oC(Tg)	Decomposition temperature: 342oC
Conductivity: 1.9 mS/cm	Electrochemical window: 3.4 (Pt)
Viscosity: 160cp	Density: 1.21g/cm3

 
Our company has been engaged in the R&D, production of ionic liquids and related technologies for more than ten years. Since 2007, our company has supplied ionic liquid reagents to customers, and can provide customers with ionic liquid products from grams to hundreds of tons. The main product series are: Imidazolium ionic liquids, single-substituted Im ionic liquids, Disubstituted Im ionic liquids, Tri-Substituted Im ionic liquids, Pyrilidinium ionic liquids, Ammonium ionic liquids, Phosphonium ionic liquids, Pyrrolidinium ionic liquids, Piperidinium ionic liquids, Functionized ionic liquids, Vinyl-Based ionic liquids, Hydroxyl-Based ionic liquids, Ether-Based ionic liquids, Ester-Based ionic liquids, Carboxyl-Based ionic liquids, Nitrile-Based ionic liquids, Amido-Based ionic liquids, SulfoAcid-Based ionic liquids, Benzyl-Based ionic liquids, Guanidine-Based ionic liquids, Oxonium salts



Related News: The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform.3179-47-3 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?158275-79-7 The fine and functional chemicals sector provides new growth drivers.5-amino-2-metilbencenosulfonamida CAS:6973-09-7 The fine and functional chemicals sector provides new growth drivers.The fine and functional chemicals sector provides new growth drivers.